Abstract Electron paramagnetic resonance (EPR) imaging is an emerging modality that can detect and localize paramagnetic molecular probes (so-called spin probes) in vivo. We previously demonstrated that nitroxide spin probes can be encapsulated in liposomes at concentrations exceeding 100 mM, at which nitroxides exhibit a concentration-dependent quenching of their EPR signal that is analogous to the self-quenching of fluorescent molecules. Therefore, intact liposomes encapsulating high concentrations of nitroxides exhibit greatly attenuated EPR spectral signals, and endocytosis of such liposomes represents a cell-activated contrast-generating mechanism. After endocytosis, the encapsulated nitroxide is liberated and becomes greatly diluted in the intracellular milieu. This dequenches the nitroxides to generate a robust intracellular EPR signal. It is therefore possible to deliver a high concentration of nitroxides to cells while minimizing background signal from unendocytosed liposomes. We report here that intracellular EPR signal can be selectively generated in a specific cell type by exploiting its expression of Human Epidermal Growth Factor Receptor 2 (HER2). When targeted by anti-HER2 immunoliposomes encapsulating quenched nitroxides, Hc7 cells, which are novel HER2-overexpressing cells derived from the MCF7 breast tumor cell line, endocytose the liposomes copiously, in contrast to the parent MCF7 cells or control CV1 cells, which do not express HER2. HER2-dependent liposomal delivery enables Hc7 cells to accumulate 750 lM nitroxide intracellularly. Through the use of phantom models, we verify that this concentration of nitroxides is more than sufficient for EPR imaging, thus laying the foundation for using EPR imaging to visualize HER2-overexpressing Hc7 tumors in animals.
Introduction
Detecting micrometastatic breast tumor lesions remains a persistent challenge for current imaging methods, but one that has clear clinical implications. Even when current detection methods reveal no clinical evidence of metastasis, disseminated tumor cells can be found in the bloodstream and bone marrow of 60% of breast cancer patients [1] . In 32% of patients whose lymph nodes were scored negative by routine histopathology, serial sectioning and immunohistochemistry nonetheless revealed micrometastases [2] . Such disseminated and micrometastatic tumor cells predict poor patient survival [1, 2] , but tend to divide slowly; therefore, they can be highly resistant to conventional chemotherapy [3] . The ability to detect micrometastases and monitor their response to therapies could be significantly improved by imaging methods that can be targeted to specific characteristics of the tumor cell with increased resolution and sensitivity.
Very-low-frequency electron paramagnetic resonance imaging (EPRI) is an attractive emerging modality for imaging metastatic breast tumor lesions. EPRI can detect and image paramagnetic species in vivo and in real time [4] . Endogenous paramagnetic molecules are too scarce to be detected by EPRI; therefore, exogenous ''spin probes'' such as nitroxides must be used to label features of interest. EPRI using nitroxides offers several advantages. First, the radiofrequency waves used to excite resonance penetrate tissues well, enabling deep-tissue imaging with high signalto-noise ratio (SNR) and high spatial resolution. Second, the magnetic moment of the electron, which is imaged by EPRI, is *660-fold greater than that of the proton [5] . This makes EPRI potentially more sensitive than proton magnetic resonance imaging (MRI). Third, spin probes can be designed to be sensitive to cellular physiology; therefore, in addition to localizing a tumor, they can also report on its physiology. Physiological parameters that can be measured with spin probes include tissue oxygen tension [6, 7] , microviscosity [8] , pH [9] , temperature [10] , and redox status [11] .
We previously synthesized nitroxides that are well retained by cells and thus exhibit long-lived intracellular signals that can be imaged by EPRI [12, 13] . We have also shown that nitroxides, like fluorophores, when encapsulated in liposomes at high concentrations ([100 mM), show concentration-dependent signal quenching. Thus, intact liposomes containing quenched probes are spectroscopically invisible. After endocytosis by cells, however, lysis of the liposomes liberates and dilutes the encapsulated probes into the cell; the resulting dequenching of the probe signal renders the cell visible [14] . Encapsulation of probes at high concentration minimizes background signal from unendocytosed liposomes and creates a cell-activated contrast-generating mechanism. By itself, however, liposomal delivery is limited by the inability to deliver probe molecules selectively to a particular cell type.
As a tool for delivering imaging agents to a physiologically distinct tissue such as a breast tumor, liposomes must be targetable, i.e., they must incorporate features that enable selective uptake in a tissue of interest, but not in other, indifferent, tissues. Liposomal surfaces can be readily decorated with moieties that target them to a specific tissue. For example, immunoliposomes, bearing surface-conjugated antibody fragments, can target distinct antigens. Specifically, immunoliposomes targeted against the human epidermal growth factor receptor 2 (HER2) have been used to enhance delivery of chemotherapeutics to HER2-expressing tumors [15, 16] .
HER2 is a receptor-tyrosine-kinase in the erbB family [17] . It is overexpressed in some breast, ovarian, and nonsmall-cell lung cancers [18] . Approximately 30% of primary breast tumors have HER2 overexpression [19, 20] , which is associated with cell proliferation, tumor progression [21] , and poor clinical prognosis [20] . Therefore, HER2 is an important target for diagnostics and therapeutics. One major therapeutic advance has been the development of humanized monoclonal antibodies against HER2 (e.g., trastuzumab). Trastuzumab binds the extracellular domain of HER2 and inhibits tumor progression through several mechanisms. Binding of HER2 by trastuzumab potentially inhibits receptor heterodimerization, which is required for RTK signaling [22] ; it also induces HER2 internalization, which limits receptor activation [23] [24] [25] .
While trastuzumab has therapeutic activity, it has garnered attention as a targeting agent for HER2. The receptor-mediated endocytosis of HER2 consequent to therapeutic antibody binding makes trastuzumab an ideal targeting agent for delivering xenobiotics to HER2-expressing cells. Antibody-mediated targeting of HER2 has been used to deliver different imaging diagnostics to HER2-overexpressing tumor cells. The approaches generally involve attaching imaging probes directly to the antibody, including near-infrared fluorophores for in vivo optical imaging [26] , radionuclides for positron emission tomography [27] , and superparamagnetic iron oxide for MRI [28] . In view of these developments, we surmised that EPRI probes could be delivered to HER2-overexpressing breast tumor cells by anti-HER2 immunoliposomes.
Immunoliposomes are an attractive alternative to delivery approaches in which ''cargo'' molecules are conjugated directly to the antibody. Such approaches deliver only a few molecules per antibody, and are therefore not efficient for imaging applications, where large numbers of probe molecules must be delivered to maximize imageable signal. Immunoliposomes encapsulating high concentrations of nitroxides can deliver large quantities of molecular probes upon endocytosis by the targeted cell, while contributing minimal background signal in circulation.
We have generated a stable HER2-overexpressing cell line, Hc7, from MCF7 human breast tumor cells. 
Materials and methods

General materials and methods
Dipotassium (2,2,5,5-tetramethylpyrrolidin-1-oxyl-3-ylmethyl)-amine-N,N-diacetate (nitroxide 1, Fig. 1 ) was synthesized as described previously [12] . 6-Carboxyfluorescein (CF) and 3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxyl (nitroxide 2, Fig. 1 
Derivation of Hc7 cells that stably overexpress HER2
To a 10-fold dilution of Fugene-6 (Roche, Indianapolis, IN) in serum-and antibiotic-free DMEM, pcDNA3.1 vector incorporating HER2 cDNA and a hygromycin selection marker (gift from Dr. Anne Hamburger, University of Maryland, Baltimore) was added (39 lg/ml) and incubated for 30 min; 100 ll of this mixture were added to 8 ml of FBS-containing antibiotic-free DMEM and used to transfect 2 9 10 5 MCF7 cells plated on 60-mm plastic Petri dishes. After 24 h, the medium was replaced with fresh DMEM containing FBS and Pen/Strep. At 96 h posttransfection, hygromycin B (500 lg/ml) was added. Antibiotic-resistant colonies were isolated and passaged more than ten times prior to analysis for HER2 overexpression.
Western immunoblotting
Hc7 cells were lysed in radio-immunoprecipitation assay buffer. Total protein (50 lg) was resolved by SDS-PAGE under reducing conditions. Proteins were transferred to Hybond-ECL membranes (Biorad, Hercules, CA) and probed with rabbit-anti-human antibodies against phospho-HER2 and b-actin (Millipore, Billerica, MA). Secondary hybridization with horseradish peroxidase (HRP)-conjugated, anti-rabbit antibodies was visualized with an enhanced chemiluminescence kit (Biorad).
Trastuzumab Fab
0 fragments for immunoliposomes and immunostaining Trastuzumab (10 mg, 8 mg/ml in 20 mM Na acetate, pH 4.5) was added to 125 ll of immobilized pepsin gel (Pierce, Rockford, IL) which had been washed three times in the same buffer. Digestion (37°C, 4 h) yielded F(ab 0 ) 2 fragments and was stopped by raising the pH to 6.5 with 1 M Tris; the pepsin gel was removed by centrifugation.
Reduction with 50 mM cysteamine for 45 min at 37°C converted the F(ab 0 ) 2 fragments into Fab 0 fragments. The reaction mixture was chromatographed on Sephadex G-15 equilibrated with elution buffer [100 mM NaCl, 50 mM Na citrate (pH 6.7), 2 mM EDTA] that was purged with N 2 for 30 min. During elution, the buffer reservoir was sparged with N 2 . Fractions containing Fab 0 were collected under N 2 , immediately frozen in liquid N 2 , and stored at -80°C until used for making immunoliposomes.
For immunofluorescence experiments, Fab 0 fragments were incubated with maleimide (20 mM, 4°C, 8 h) under N 2 to block free sulfhydryl groups. The maleimide-modified Fab 0 fragments were eluted from Sephadex G-15 with Dulbecco's Phosphate Buffered Saline (DPBS).
HER2 immunostaining MCF7, CV1, and Hc7 cells were fixed with 4% paraformaldehyde in DPBS (pH 7.4) for 20 min. All steps were at room temperature; each step was followed by three washes with DBPS. Nonspecific antigen sites were blocked with 10% (v/v) normal rabbit serum in DBPS for 1 h. Cells were incubated for 3 h in DPBS with the following primary antibodies: trastuzumab IgG, 1 lg/ml; maleimide-inactivated trastuzumab Fab 0 , 0.38 lg/ml. The secondary antibody was fluorescein isothiocyanate (FITC)-conjugated, Fab-specific, rabbit anti-human IgG (3 lg/ml in DPBS; Jackson ImmunoResearch, West Grove, PA). Secondary hybridization was for 1 h in the dark. Labeled cells were maintained in DPBS for fluorescence microscopy.
Immunoliposome preparation
Liposomes were composed of 1,2-distearoylphosphatidylcholine (DSPC), cholesterol (Chol), ammonium N-(lissamine rhodamine B sulfonyl)-1,2-dipalmitoylphosphatidylethanolamine (Rhod-PE), and ammonium 1,2-distearoyl-sn-glycero-3-phosphatidylethanolamine-N-[maleimide-poly(ethyleneglycol)2000] (PE-PEG-maleimide) in the molar ratio 3 DSPC:2 Chol:0.06 PE-PEG-maleimide:0.003 Rhod-PE. 10-30 lmol of phospholipid in 100 ll EtOH were injected into 0.5 ml of a rapidly stirred aqueous solution of 100 mM CF or 150 mM nitroxide 1. The mixture was passed eleven times through a 100-nm porosity filter membrane in a Mini Extruder (Avanti Polar Lipids) to yield a suspension of liposomes. The extruder and all solutions were maintained at [55°C to ensure fluidity of the lipid phase. Liposomes were purified on Sephadex G-50 with the same anaerobic buffer used to purify Fab 0 fragments. Freshly prepared liposomes were incubated with Fab 0 fragments under N 2 (4°C, overnight). The immunoliposomes were purified on Sephacryl HR-200 with DPBS as eluant and stored at 4°C. Antibody coupling was verified by SDS-PAGE ( Supplemental Fig. S1 ); nitroxide retention was verified by EPR spectroscopy (Supplemental Fig. S2 ).
Cellular uptake of CF-loaded immunoliposomes
Rhod-PE-containing immunoliposomes encapsulating 100 mM CF were used as a suspension in Hanks' Balanced Salt Solution (HBSS) at a concentration of 0.025 lmol phospholipid/ml. Hc7, MCF7, or CV1 cells were incubated with 2 ml of liposome suspension at 37°C for 4 h. After three brief washes with Ca 2? -and Mg 2? -free HBSS containing 1 mM EDTA, the cells were maintained in normal HBSS for fluorescence microscopy.
Cellular uptake of nitroxide-loaded immunoliposomes
Hc7 cells in replicate 60-mm plastic Petri dishes were incubated at 37°C with Rhod-PE-containing immunoliposomes (2 ml, 0.025 lmol phospholipid/ml in HBSS) encapsulating 150 mM nitroxide 1. At various times, cells were washed with HBSS, released from the plate with trypsin-EDTA, and centrifuged at 1459g for 3 min; the resulting pellet was washed twice with Ca 2? -and Mg 2? -free HBSS containing 1 mM EDTA. The cells were resuspended in 400 ll normal HBSS, lysed with 120 lM digitonin, and sonicated for 1 min. Cell-associated nitroxide and Rhod-PE were analyzed spectroscopically. Nitroxide concentration in each sample was determined using a standard curve of EPR spectral intensity versus nitroxide concentration. Average cell count per dish was determined by counting control dishes; total intracellular volume was calculated using a measured volume of 2.5 9 10
-12 l/cell (Supplemental Fig. S3 ). The average intracellular nitroxide concentration was then estimated through volumetric calculations.
EPR spectroscopy EPR spectra were acquired using a quartz flat-cell in an X-band spectrometer (E-109, Varian, Palo Alto, CA) at the following settings: microwave power, 20 mW; frequency, 9.55 GHz; field center, 333.5 mT; modulation amplitude, 0.05 mT; modulation frequency, 100 kHz; time constant, 0.5 s. The magnetic field was scanned from 0.8 to 8 mT at 2.67 mT/min. Data acquisition was through EWWIN software (Scientific Software Services, Plymouth MI). Reported spectral intensity is the amplitude of the center peak in the nitroxide triplet spectrum (Fig. 1) .
Fluorescence spectroscopy
Fluorescence spectra were recorded on a spectrofluorometer (model CM1T-10I, SPEX Industries, Metuchen, NJ) controlled through Datamax software (Galactic Industries, Salem, NH). Excitation and emission wavelengths for Rhod-PE were 550 and 588 nm, respectively.
Fluorescence microscopy
An inverted microscope (TE200, Nikon, Tokyo, Japan) equipped with a 940 oil-immersion objective (Super Fluor, NA 1.4) was used for fluorescence microscopy. A monochromator (PolyChrome II, TILL Photonics, Gräfelfing, Germany) supplied excitation light. Fluorescence was bandpass-filtered before capture by a CCD camera (CoolSnap HQ, Roper Scientific, Tucson, AZ). Instrument control, image acquisition, and analysis were performed with MetaFluor software (Molecular Devices, Downingtown, PA).
EPR imaging, image reconstruction, and analysis
A nitroxide-impregnated agarose phantom was prepared by boiling a 4% (w/v) agarose solution, then adding 100 lM nitroxide 2 and drawing the solution into a serological pipette (6-mm i.d.). The agarose was then sectioned into 3-mm-long cylinders. The cylinder was molded in polyvinylsiloxane dental impression material (GC Dental Products, Kasugai, Japan) and centered in the resonant cavity of a 250-MHz EPR imaging spectrometer [4] fitted with a loop-gap resonator (with single loop and single gap). The sample-holding loop (19-mm diameter, 15-mm depth) had a loaded Q of 172. A 0.55-mT spectral window encompassed the central peak of the nitroxide spectrum. Instrumental parameters were: RF power, 12 dB; modulation amplitude and frequency, 0.198 mT and 4.98 kHz, respectively; lock-in time constant, 100 ms, with 100-msper-point dwell time; 64 points per projection; field gradient, 48.9 mT/m. Signal intensity in the EPR image is proportional to nitroxide EPR signal. Under identical conditions, nitroxides 1 and 2 show essentially identical EPR spectral signals (see Fig. 1 ); therefore commercially available nitroxide 2 was adequate for use in the phantom.
Continuous-wave (CW) EPR images were obtained using an essentially tomographic technique. Projections are defined as field-scanned CW spectra in the presence of a 48.9-mT/m gradient. Each scan, comprising 64 points uniformly spaced in the magnetic field, was obtained in 6.4 s; each projection was the average of four scans. Sixtysix projections were acquired at 10 polar angles; multiple azimuthal angles were sampled at each polar angle. A filtered back-projection algorithm was used for image reconstruction [29] . Projections were filtered using a simple cutoff of the image response frequency to half the Nyquist sampling limit.
Spatial resolution of an imaging system is commonly defined by the full-width-at-half-maximum (FWHM) of a point spread function (PSF). For a phantom cylinder of known dimensions, the FWHM can be estimated from the edge profile of signal intensity [30] . A two-dimensional cross section from the reconstructed image, taken through the center of the cylinder and orthogonal to the axis, was analyzed. Twenty intensity profiles uniformly spaced around the circumference of the cylinder were analyzed to yield an average FWHM of 4.4 ± 0.4 mm. To determine SNR, the mean signal intensity in a region-of-interest (ROI) containing signal was ratioed against the standard deviation of the noise in an identically sized ROI containing only noise.
Results
Hc7 cells express high levels of HER2
at the plasma membrane MCF7 breast tumor cells were stably transfected to overexpress HER2. HER2 expression in the resulting Hc7 transfectants were analyzed by western blot (Fig. 2) . The blot confirms that when compared to MCF7 cells, Hc7 cells have much higher HER2 expression, but provides no information regarding subcellular HER2 localization. Because immunoliposomes can only target receptors that are accessible extracellularly, it is important to verify that HER2 is highly expressed at the cell surface. Hc7, MCF7, and CV1 cells were fixed with paraformaldehyde but without detergents, immunostained with trastuzumab IgG as the primary antibody and a FITC-conjugated, Fab-specific secondary antibody, and analyzed by fluorescence microscopy (Fig. 3) . CV1 cells, which are African Green Monkey kidney epithelial cells, do not express the exclusively human HER2 receptor, and were used as the control for nonspecific labeling. As shown in Fig. 3a , Hc7 cells express HER2 abundantly at the cell surface, whereas untransfected MCF7 cells show only very feeble HER2 expression. As the quantitative summary in Fig. 3b shows, immunofluorescence in Hc7 cells was much greater than in MCF7 and in the negative-control CV1 cells (ANOVA F 2,36 = 75.97).
Trastuzumab Fab
0 fragments retain antigen-binding ability Intact trastuzumab avidly binds HER2, but the antibody must be proteolyzed and reduced to generate Fab 0 fragments that can be conjugated to liposomes. To assess the antigen-binding affinity and selectivity of the Fab 0 fragments, Hc7, MCF7, and CV1 cells were immunostained as outlined above, with the exception that primary antibodies were Fab 0 fragments whose exposed reactive thiol groups had been inactivated with maleimide (Fig. 4) . Immunofluorescence was again much greater in Hc7 cells than in MCF7 and in negative-control CV1 cells (ANOVA F 2,38 = 31.38). Moreover, when ANOVA is performed on the combined data from Figs. 3b and 4b, post hoc analysis reveals that in each cell line, regardless of whether the intact IgG or the Fab 0 fragment was used as the primary free, EDTA-containing HBSS, and then maintained in normal HBSS for fluorescence imaging (Fig. 5) . As shown in Fig. 5 (panels a-c) , Hc7 cells exhibit bright intracellular CF fluorescence (green) as the result of immunoliposome internalization and subsequent release and dequenching of the encapsulated CF. The Hc7 cells also show intense, more spatially nonuniform, intracellular Rhod-PE fluorescence (red), which is indicative of incorporation of Rhod-PE lipid from the immunoliposomes into intracellular membranes. In contrast, MCF7 cells, which express only physiological levels of HER2, endocytose few immunoliposomes and thus show very feeble intracellular CF and Rhod-PE fluorescence (Fig. 5, panels d-f) . Lastly, CV1 cells, which do not express HER2, have no detectable fluorescence signals (Fig. 5, panels g-i) . These results indicate that endocytic uptake of immunoliposomes is dependent on HER2 expression, and that it is possible to generate intense intracellular signals selectively in HER2-overexpressing breast tumor cells.
Hc7 cells achieve high intracellular nitroxide concentrations through endocytosis of immunoliposomes
Replicate dishes of Hc7 cells were incubated with immunoliposomes incorporating Rhod-PE, and encapsulating 150 mM nitroxide 1. At various times, cells were trypsinized and washed with Ca 2? -and Mg 2? -free, EDTA-containing PBS. The amount of nitroxide and Rhod-PE associated with the cells was determined spectroscopically as described in ''Materials and methods''. Cell-associated nitroxide and Rhod-PE initially increased in parallel with time of incubation (Fig. 6) , as expected from endocytic uptake of liposomes and their luminal contents. At 6 h, cell-associated nitroxide peaked at *750 lM. By 9 h, intracellular nitroxide concentration had declined to *350 lM, whereas cell-associated Rhod-PE was unchanged from the level observed at 6 h. This suggests that beyond 6 h, endocytosis became very slow. Without continued uptake of liposomes for replenishment, cellular transport processes that extrude nitroxides [12] dominated, leading to a net loss of intracellular nitroxide signal. Even so, intracellular nitroxide concentrations were in the several hundred micromolar range. Agarose phantom containing 100 lM nitroxide can be visualized by EPRI with high contrast To investigate the possibility of imaging Hc7 cells that have selectively accumulated nitroxides through endocytosis of immunoliposomes, we constructed an EPR imaging phantom consisting of an agarose cylinder impregnated with 100 lM nitroxide 2. The phantom was readily imaged by EPRI (Fig. 7) with a SNR of 79. The known geometry of the cylinder is well represented in the EPR image, which has a spatial resolution of 4.4 ± 0.4 mm. These findings indicate that if immunoliposomal delivery could cause Hc7 cells in vivo to accumulate nitroxide at concentrations comparable to those observed in vitro (Fig. 6) , then Hc7 tumors can be easily imaged by EPRI.
Discussion
We have demonstrated that anti-HER2 immunoliposomes encapsulating quenched fluorophores and nitroxides can be targeted to, and generate robust spectral signals in, Hc7 cells, which overexpress HER2. This study, by showing that immunoliposomes enable cell-activated contrast generation only in the targeted cell type, significantly enhances the utility of our earlier finding that endocytosis of liposomes can serve as a cell-activated contrast-generating mechanism [14] , For this study we generated a new cell line, Hc7, from the MCF7 breast tumor line. Hc7 cells overexpress HER2 at the cell surface and thus can be targeted by anti-HER2 immunoliposomes. Immunofluorescence showed that the HER2 expression level in Hc7 cells is comparable to what has been observed in other HER2-overexpressing tumor lines such as A431 or BT-474 [31] . Anti-HER2 immunoliposomes encapsulating CF are avidly and selectively endocytosed by Hc7 cells (Fig. 5) . After subsequent liposomal degradation and release of the quenched fluorophores, dequenching results in intense intracellular CF fluorescence. Endocytosis of immunoliposomes bearing trastuzumab Fab 0 fragments clearly depends on cellular HER2 expression: MCF7 and CV1 cells, which have physiological or no HER2 expression, respectively, take up immunoliposomes either very feebly or not at all, and do not show robust intracellular fluorescence.
As vehicles for delivering fluorescent and EPR imaging agents to tumor cells, immunoliposomes have inherent advantages. Because the liposomes encapsulate imaging probes at self-quenching concentrations, they are spectroscopically ''dark'' (see Supplemental Fig. S2 ; [14] ). This minimizes background signal from unendocytosed liposomes. After endocytosis, release and dilution of the encapsulated probes into the cell dequenches the probe signal, causing the cell to become spectroscopically ''bright''. Moreover, in contrast to targeting mechanisms where an antibody is directly labeled with molecular probes, immunoliposomes efficiently deliver high levels of imaging agents to cells for improved SNR in imaging. For example, each endocytosed liposome with an outer diameter of 100 nm and encapsulating 150 mM molecular probes delivers *34,000 probe molecules. The consequent signal amplification is essential for EPRI. Immunoliposome uptake enabled Hc7 cells to accumulate nitroxide intracellularly at *750 lM (Fig. 6) , which is ample for EPRI with high SNR (Fig. 7) .
Using immunoliposomes to deliver nitroxides to HER2-overexpressing tumors in vivo requires additional considerations. First, liposomes are cleared from circulation by the reticulo-endothelial system (RES) [32] , and must be engineered to evade such clearance. Incorporating into the liposomes a small proportion of lipid conjugated to poly(ethyleneglycol) (PEG) retards clearance by the RES [33] . The longer circulation times of such sterically stabilized, ''PEGylated'' liposomes enhance their targeting potential in vivo. Second, liposome delivery to tumor cells depends on tumor vascularization. While a previous study of immunoliposomes in a xenograft model suggests relatively uniform micro-distribution within tumors [34] , the macro-distribution could be inhomogeneous owing to differential vascularization. Because liposomes may access only a fraction of the tumor volume, despite the very high intracellular concentrations potentially achievable with The cylinder is 6 mm in diameter and 3 mm in length. Cross-sectional view shown is from the approximate center of the cylinder's axial dimension. The known geometry of the cylinder is well represented in the image. Signal from the cylinder is imaged with a signal-to-noise ratio of 79 and a spatial resolution of 4.4 mm. All axis labels are in centimeters and spectral intensity is encoded according to the scale shown on the right immunoliposomal delivery, the total nitroxide content of the entire tumor may still be modest. This motivates additional innovations to enhance SNR. SNR in EPRI can be improved by delivering more nitroxide molecules to cells, and by optimizing the spectroscopic properties of the molecules themselves. Although larger liposomes can encapsulate more nitroxide, liposomes with 100-nm outer diameter are already near-optimal in vivo. Increasing the diameter leads to increased circulatory clearance and reduced extravasation, both of which offset the advantage of the larger luminal volume [35, 36] . Fortunately, the performance of nitroxides as EPR imaging agents can be improved through rational design. First, we can synthesize nitroxides that are zwitterionic at physiologic pH. Such nitroxides would be highly water-soluble but would require no counter ions, which normally increase the osmolarity of the encapsulated solution but contribute no imageable signal. Zwitterionic nitroxides can be encapsulated at 300 mMtwice the concentration of nitroxide 1, which is a mono-anion at physiological pH. Second, we can synthesize deuteriumand 15 N-substituted nitroxides, which have narrower spectral peaks and correspondingly larger peak amplitudes. Preliminary studies indicate that for nitroxide 2, isotopic substitution increases the EPR peak amplitude by close to 10-fold (unpublished observations). These two improvements should significantly enhance the feasibility of visualizing Hc7 tumors in vivo by EPR imaging.
EPRI is an emergent imaging modality that could offer sensitive detection of HER2-overexpressing tumors, and useful insight into their physiology. The demonstration that it is possible to use anti-HER2 immunoliposomes to deliver high concentrations of nitroxides selectively to HER2-overexpressing tumor cells bodes well for high-contrast EPRI of HER2-overexpressing tumors. Current efforts are aimed at developing Hc7 xenograft models, increasing persistence of immunoliposomes in circulation, and optimizing nitroxide molecular structure for EPRI.
